香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 山東新華製藥股份有限公司 Shandong Xinhua Pharmaceutical Company Limited （於中華人民共和國註冊成立的股份有限公司） （股份代碼：00719） 臨時股東大會投票結果 臨時股東大會於2025年10月24日（星期五）在中國山東省淄博市高新區魯泰大道1號舉行。日期 為2025年10月2日之臨時股東大會通告所載之所有已提呈決議案，在臨時股東大會上以投票方式 正式通過。截至臨時股東大會日期，本公司已發行股份總數為689,776,535 股，包括494,776,535 股A股及195,000,000 股H股。 1 臨時股東大會出席情況及投票結果 臨時股東大會出席情況 臨時股東大會出席情況如下： | 出席臨時股東大會現場會議（不論親身或由代理代表）及以網絡投票參加臨時 | 532 | | --- | --- | | 股東大會的股東人數 | | | 其中： 出席臨時股東大會現 ...

Core Viewpoint - Xinhua Pharmaceutical's stock has experienced fluctuations, with a recent decline of 2.01% and a total market capitalization of 11.099 billion yuan, indicating a mixed performance in the market [1] Company Overview - Xinhua Pharmaceutical, established on November 20, 1998, and listed on August 6, 1997, is located in Zibo, Shandong Province. The company specializes in the development, manufacturing, and sales of chemical raw materials, pharmaceutical preparations, and other products [1] - The main business revenue composition includes 44.36% from tablets, injections, and capsules, 32.11% from raw materials for antipyretic and analgesic drugs, and 23.53% from pharmaceutical intermediates and others [1] Financial Performance - For the first half of 2025, Xinhua Pharmaceutical reported operating revenue of 4.639 billion yuan, a year-on-year decrease of 1.98%, and a net profit attributable to shareholders of 224 million yuan, down 15.69% year-on-year [2] - The company has cumulatively distributed 1.17 billion yuan in dividends since its A-share listing, with 495 million yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders for Xinhua Pharmaceutical was 76,500, a decrease of 1.77% from the previous period. The average number of circulating shares per shareholder remained unchanged at 6,442 shares [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 3.4094 million shares, an increase of 1.066 million shares from the previous period [3]

Core Viewpoint - The article discusses the increasing health concerns related to low immunity and oxidative stress due to modern lifestyle factors, highlighting the importance of Coenzyme Q10 (CoQ10) as a natural antioxidant and its role in health maintenance [1][2]. Company Overview - Xinhua Pharmaceutical has launched a new product, Xinhua Coenzyme Q10 Soft Capsules, aimed at enhancing immunity and providing antioxidant support [1][4]. - The product contains 40mg of CoQ10 per capsule, which is significantly higher than the average dietary intake, addressing the gap in daily nutritional needs [2]. Product Details - The recommended daily intake of CoQ10 is 30-50mg, while typical dietary sources provide only 2-5mg, making supplementation necessary for those with specific health conditions [2]. - The CoQ10 used in the product is derived from microbial fermentation, ensuring a purity greater than 99%, which is more effective than chemically synthesized alternatives [3]. Nutritional Benefits - CoQ10 plays a crucial role in various physiological processes, including ATP production, free radical scavenging, and enhancing cellular metabolism, which are vital for maintaining health [1][3]. - The product also includes sunflower seed oil, which is rich in unsaturated fatty acids and vitamin E, providing a synergistic antioxidant effect when combined with CoQ10 [3]. Market Position - Xinhua Pharmaceutical's Fuyuan brand has a commitment to high-quality health products, and the introduction of CoQ10 soft capsules is expected to meet the growing consumer demand for health supplements [4].

Core Insights - Levodopa is a key medication for treating Parkinson's disease, alleviating symptoms such as muscle stiffness, tremors, and slow movement. It also shows potential for treating Alzheimer's disease, chronic pain, and constipation, with broad applications in biomedical and materials science fields [1][3][4]. Industry Overview - The levodopa market has seen continuous growth in demand due to an aging population and increasing Parkinson's disease cases. The market was negatively impacted by the pandemic from 2020 to 2022, but sales began to recover in 2023, reaching 31.83 million yuan in 2024 [1][7][8]. Industry Chain - The levodopa industry chain consists of upstream suppliers of chemical raw materials and excipients, midstream research and manufacturing processes, and downstream applications in medical institutions, pharmacies, and patients. The number of Parkinson's patients significantly influences the industry's development, with over 3 million patients aged 65 and above in China [6][7]. Competitive Landscape - The global levodopa market is dominated by a few large pharmaceutical companies, such as Merck & Co. and Pfizer, while domestic companies primarily focus on generic drugs. Key players in China include Shandong Xinhua Pharmaceutical Co., Zhejiang Huahai Pharmaceutical Co., and others [8][9]. Industry Development Trends - Market demand for levodopa is expected to continue increasing due to the rising incidence of Parkinson's disease and improvements in healthcare systems in emerging countries [10]. - Technological advancements in biopharmaceuticals are likely to enhance levodopa production processes, leading to improved efficiency and product quality. Companies are expected to develop various formulations, such as sustained-release and controlled-release preparations, to enhance patient experience [11]. - The globalization of the levodopa industry presents opportunities for companies to expand into international markets, increasing brand recognition and competitiveness [12].

Core Viewpoint - Xinhua Pharmaceutical's stock has shown fluctuations with a recent increase of 2.02%, reflecting a total market capitalization of 11.52 billion yuan and a year-to-date price increase of 8.02% [1] Company Overview - Xinhua Pharmaceutical, established on November 20, 1998, and listed on August 6, 1997, is located in Zibo, Shandong Province. The company specializes in the development, manufacturing, and sales of chemical raw materials, pharmaceutical preparations, and other products [1] - The main business revenue composition includes 44.36% from tablets, injections, and capsules; 32.11% from raw materials for antipyretic and analgesic drugs; and 23.53% from pharmaceutical intermediates and others [1] Financial Performance - For the first half of 2025, Xinhua Pharmaceutical reported operating revenue of 4.639 billion yuan, a year-on-year decrease of 1.98%, and a net profit attributable to shareholders of 224 million yuan, down 15.69% year-on-year [2] - Cumulatively, the company has distributed 1.17 billion yuan in dividends since its A-share listing, with 495 million yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders for Xinhua Pharmaceutical was 76,500, a decrease of 1.77% from the previous period. The average circulating shares per person remained unchanged at 6,442 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 1.066 million shares to 3.4094 million shares, and several ETFs that also increased their holdings [3]

Core Viewpoint - Xinhua Pharmaceutical's stock has shown fluctuations with a recent increase of 2.07%, reflecting a total market capitalization of 11.21 billion yuan, while facing net outflows of major funds [1][2]. Group 1: Stock Performance - As of October 20, Xinhua Pharmaceutical's stock price reached 16.25 yuan per share, with a trading volume of 1.30 billion yuan and a turnover rate of 1.65% [1]. - Year-to-date, the stock has increased by 5.11%, with a 3.90% rise over the last five trading days, but a decline of 5.63% over the past 60 days [1]. - The company has appeared on the "Dragon and Tiger List" once this year, with a net purchase of 15.67 million yuan on January 6 [1]. Group 2: Financial Performance - For the first half of 2025, Xinhua Pharmaceutical reported a revenue of 4.639 billion yuan, a year-on-year decrease of 1.98%, and a net profit attributable to shareholders of 224 million yuan, down 15.69% year-on-year [2]. - Cumulative cash dividends since the A-share listing amount to 1.17 billion yuan, with 495 million yuan distributed over the last three years [3]. Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders decreased to 76,500, with an average of 6,442 circulating shares per person [2]. - Major shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 1.066 million shares, and several ETFs that also increased their positions [3].

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the marketing of Fumarate Bisoprolol Tablets, which are indicated for hypertension, coronary heart disease (angina), and chronic stable heart failure with reduced left ventricular systolic function (ejection fraction ≤ 35%) [1] Summary by Category Product Approval - The approval includes the issuance of a Drug Registration Certificate for Fumarate Bisoprolol Tablets [1] - The product is intended for use under medical supervision alongside ACE inhibitors, diuretics, and selectively used cardiac glycosides [1] Indications - Fumarate Bisoprolol Tablets are indicated for the treatment of: - Hypertension - Coronary heart disease (angina) - Chronic stable heart failure with reduced left ventricular systolic function (ejection fraction ≤ 35%) [1]

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration certificate of Fumarate Bisoprolol Tablets, indicating a significant advancement in its product portfolio [1] Group 1: Product Approval - The Fumarate Bisoprolol Tablets are indicated for the treatment of hypertension and coronary heart disease (angina) [1] - The product is also indicated for chronic stable heart failure with reduced left ventricular systolic function (ejection fraction ≤ 35%) [1] - The use of this medication requires adherence to medical advice, including the use of ACE inhibitors, diuretics, and selectively using cardiac glycosides [1]

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received the drug registration certificate for Fumarate Bisoprolol Tablets from the National Medical Products Administration, indicating a significant advancement in its product portfolio [1] Group 1: Product Approval - The approval is for Fumarate Bisoprolol Tablets, which are indicated for hypertension and coronary heart disease (angina) [1] - The product is also indicated for chronic stable heart failure with reduced left ventricular systolic function (ejection fraction ≤ 35%) [1] Group 2: Treatment Guidelines - The use of Fumarate Bisoprolol Tablets should be accompanied by ACE inhibitors, diuretics, and selectively used cardiac glycosides as per medical advice [1]

Core Viewpoint - The announcement indicates that Xinhua Pharmaceutical has received approval from the National Medical Products Administration for the registration of Fumarate Bisoprolol tablets, which are indicated for hypertension, coronary heart disease (angina), and chronic stable heart failure with reduced left ventricular systolic function (ejection fraction ≤ 35%) [1] Group 1 - The approved drug, Fumarate Bisoprolol, targets specific cardiovascular conditions [1] - The estimated sales revenue for Fumarate Bisoprolol tablets in Chinese public medical institutions is approximately RMB 1.228 billion in 2024 [1]